Navigation Links
Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
Date:4/9/2008

- CDAS Expands Offering to Include Screening for Targeted Cancer Drugs

Using Genetically-Defined In-Vitro Human Disease Models -

HOPKINTON, Mass., April 9, 2008 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a partnership with Horizon Discovery Ltd. (Cambridge, UK) that expands Caliper Discovery Alliances and Services' (CDAS) oncology cell line and screening capabilities for testing single drugs and combination therapies. Through this alliance, CDAS now offers unique, genetically-defined, and isogenic human cancer cell lines that allow researchers to better identify and characterize personalized drugs targeted at a specific subset of patients.

Isogenic cell-line pairs, where one cell line contains a genetic alteration or mutation of interest and the other contains the normal gene, represent cell-based models that accurately portray specific human diseases in the context of their matched normal genetic backgrounds. The inclusion of isogenic cell-line pairs in the discovery process enables scientists to better understand the mechanism of action of lead compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new therapeutic indications, assess the efficacy of drug combinations, and identify potential side effects earlier in the discovery process.

"The alliance with Horizon Discovery adds significant value to existing CDAS offerings and illustrates Caliper's commitment to providing accurate in vitro and in vivo models for oncology research," said David Manyak, Executive Vice President of Drug Discovery Services, Caliper Life Sciences. "The addition of Horizon's isogenic cell lines to our existing oncology cell prol
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Caliper Life Sciences Announces Date and Location of its 2008 Annual Meeting of Stockholders
2. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
3. Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference
4. Caliper Life Sciences to Present at Cowen and Company 28th Annual Health Care Conference
5. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
6. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
7. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
10. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
11. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the year ended December 31, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... did not provide the outcome management and investors ... at iCo Therapeutics", said Andrew Rae , ...
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... -- Haemonetics Corporation (NYSE: HAE ) today reported ... $226.5 million, down 6%.  Excluding currency impact, revenue ... reported a fourth quarter GAAP net loss of ... income, exclusive of transformation, restructuring and deal amortization ... and adjusted earnings per share were $0.47, up ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... CITY , May 6 /PRNewswire-FirstCall/ - Aeterna ... late-stage drug development company specialized in oncology and endocrinology, ... Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, ... ovarian cancer. AEZS-108 is currently in a Phase 2 ...
... Wheat aleurone is a novel wheat grain fraction ... clinical trials with ready-to-eat cereals and bread containing ... blood concentrations of tentatively beneficial compounds such as ... both associated with heart disease risk. It ...
... CHARLOTTE, N.C. , May 5 The untimely death ... addiction to the forefront of American media recently. The good news for ... pain relief. , , ... of those options is called radiofrequency thermocoagulation therapy. Used to treat pain ...
Cached Biology Technology:Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3Medication Doesn't Have to be the Answer to Pain; Southeast Pain Care Offers Pill-free Pain Relief 2
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... the way to go, if you are a primate crossing ... researchers have measured the energy required to navigate a forest ... in the trees. Their work was presented at the Society ... 2012. The findings help us to understand why ...
... discovered that recent climate change is causing leaves of some ... is the first of its kind in the world, highlights ... The results are published online today in the Royal ... analysed leaves from herbarium specimens of Narrow-leaf Hopbush ( Dodonaea ...
... resource developed at the San Diego Supercomputer Center ... is helping thousands of researchers worldwide unravel the ... among virtually every species on the planet. ... Infrastructure for Phylogenetic RESearch), created by SDSC researchers, ...
Cached Biology News:Shrinking leaves point to climate change 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 3
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: